OKLAHOMA CITY (July 21, 2026) – Attorney General Gentner Drummond today applauded President Trump and the Federal Trade Commission following the announcement of a proposed settlement with CVS Caremark, one of the nation's largest pharmacy benefit managers (PBMs). The settlement would increase transparency, promote fair competition and help lower prescription drug costs for the health plans that ultimately bear them.
"This proposed settlement represents another important step toward restoring accountability in the prescription drug marketplace," Drummond said. "President Trump and the FTC deserve credit for continuing to pursue reforms that put patients, employers and health plans ahead of opaque business practices."
The proposed settlement follows a similar agreement the FTC reached with Express Scripts earlier this year and would require Caremark to overhaul its pricing, rebate and reimbursement practices.
Drummond has made PBM accountability a priority under state law, investigating below-cost reimbursement, reimbursement appeal practices and transparency issues affecting patients, independent pharmacies and health plans. Oklahoma's enforcement relies on state law, while the FTC acts under federal antitrust authority. Both efforts are aimed at the same objective: greater transparency, fair competition and accountability in the prescription drug marketplace.
"Meaningful PBM reform requires leadership at every level of government," Drummond said. "The Trump Administration has demonstrated a strong commitment to bringing greater accountability and transparency to the prescription drug marketplace. Oklahoma shares that commitment, and we stand ready to assist our federal partners while continuing to aggressively enforce Oklahoma law to protect patients, pharmacies and the health plans that serve Oklahomans."
The proposed consent agreement is subject to a 30-day public comment period before the FTC decides whether to finalize it.
